Absent some major announcement related to Lpathomab, my prediction is this company is done in six to twelve months. More than six months of looking for a partner for ASONEP with no announcement doesn't bode well for an even less than "less than stellar" iSONEP. Even then they have zero leverage unless there is a bidding war which is extremely unlikely in my opinion.
My last post. This is now a write-off. Good luck to those of you here who choose to continue to have your hand bitten by these guys. As I said before - Toxic management = toxic investment regardless and this is definitely a toxic investment for me. Lesson learned - Don't believe the hype. Bye.
Appears your sources have some validity after all although it still seems questionable to me whether there is enough meat there for anyone to take on the cost of extending this study. The big question we still don't have unless it was passed verbally at the conference is "Why?".
Once again kudos to the company for leaving it's investors out of the loop. If there was any information of value passed verbally at the conference, clearly the doctors (if so inclined) now have an advantage over the shareholders.